multiple sclerosis (MS)
Conditions
Brief summary
The change in the values of the MFIS questionnaire is considered as the main study variable for the evaluation of effectiveness.
Detailed description
- Patient-perceived quality of life. The change in the mean score of the patient-perceived quality of life scale (SF-12) between the time of inclusion in the study and at the beginning and end of each phase will be assessed. - Beck Depression Inventory-II to assess depressive symptomatology. The assessment will be made at inclusion, and at the beginning and end of each phase. - Total costs per patient. Total costs of hospitalisation and treatment as well as other health care will be measured. -
Interventions
DRUGAmantadine Level 100 mg cápsulas duras
Sponsors
Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in the values of the MFIS questionnaire is considered as the main study variable for the evaluation of effectiveness. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Patient-perceived quality of life. The change in the mean score of the patient-perceived quality of life scale (SF-12) between the time of inclusion in the study and at the beginning and end of each phase will be assessed. - Beck Depression Inventory-II to assess depressive symptomatology. The assessment will be made at inclusion, and at the beginning and end of each phase. - Total costs per patient. Total costs of hospitalisation and treatment as well as other health care will be measured. - | — |
Countries
Spain
Outcome results
None listed